Dr. Zhengqiang Yang 杨正强
Chief Physician
Department of Interventional Therapy, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Ablation and vascular interventional therapy for malignant tumors, including liver cancer, lung cancer, and bile duct cancer.
Dr. Yang holds a medical doctorate and serves as a Chief Physician and doctoral supervisor. The doctor specializes in interventional radiology for benign and malignant tumors, using techniques such as transarterial chemoembolization, radiofrequency, microwave, and cryoablation, iodine-125 seed implantation, biopsy, drainage, and port implantation. Dr. Yang leads multiple national and provincial research projects.
Professional roles
- Standing Committee Member, Minimally Invasive Therapy Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Tumor Ablation Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Interventional Radiology Professional Committee, China Maternal and Child Health Care Association
- Secretary-General, Interventional Therapy Professional Committee, Beijing Cancer Society
Name order: in Chinese the family name comes first (Yang Zhengqiang). Papers usually list the name as Zhengqiang Yang or Yang Z.
Selected publications
36 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- Liver Int, 2026 (senior author): Spatial Acid-Associated Niches Inform Irinotecan-Based DEB-TACE in Colorectal Liver Metastases: A Multicentre Randomized Trial. PubMed 42969685
- J Hepatocell Carcinoma, 2026 (senior author): Baseline Sleep Quality and Objective Response in HCC Patients Treated with TACE Combined with Lenvatinib and PD-1 Inhibitors: A Secondary Analysis of a Prospectively Registered Observational Cohort. PubMed 42404105
- Hepatobiliary Surg Nutr, 2026 (senior author): Immune-mediated tumor regression and subsequent escape driven by antigen loss and major histocompatibility complex (MHC) class I downregulation following GPC3 DNA vaccination in hepatocellular carcinoma. PubMed 42273584
- Acad Radiol, 2026 (senior author): Multiparametric MRI-Based Deep Learning and Radiomics for Predicting Progression-Free Survival Benefit in Patients with Hepatocellular Carcinoma Treated with Immunotherapy and Targeted Therapy Plus Transarterial Chemoembolization: A Bicentric Study. PubMed 41723043
- Transl Gastroenterol Hepatol, 2026 (senior author): Hepatic arterial infusion chemotherapy combined with targeted immunotherapy and anticoagulation for hepatocellular carcinoma with right atrial tumor thrombus: a case report. PubMed 41675333
- Hepatobiliary Surg Nutr, 2025 (senior author): Transarterial chemoembolization combined with immunotherapy plus bevacizumab or lenvatinib for the treatment of unresectable hepatocellular carcinoma: which treatment strategy demonstrates superior efficacy?. PubMed 41104206
- Quant Imaging Med Surg, 2025 (senior author): Modified hepatic arterial infusion chemotherapy protocol for reducing perioperative pain and anesthetic consumption in patients with hepatocellular carcinoma. PubMed 41081144
- J Vasc Interv Radiol, 2025 (first author): Comparison of the Effectiveness of Inguinal Lymphangiography and Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhosis-Related Chylous Ascites. PubMed 40058580
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion